CAR-T therapies are specifically manufactured for each individual patient. It involves taking some of the patient’s own white blood cells which are then reengineered in a laboratory so they can recognise and attack cancer cells before being infused back into the patient.
DRAFT NICE guidance does not recommend use as all cost-effectiveness estimates were above range normally considered cost-effective use of NHS resources, and treatment did not meet criteria for inclusion in Cancer Drugs Fund.